Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Educating Patients on Maintenance Therapy in mUC

August 26th 2020

Changing the Standard of Care in Metastatic Bladder Cancer

August 26th 2020

Practical Management of AEs in Metastatic Bladder Cancer

August 26th 2020

Safety Data from JAVELIN Bladder 100

August 26th 2020

Increased Survival Outcomes with Switch Maintenance in mUC

August 26th 2020

Switch Maintenance Strategy for Metastatic Bladder Cancer

August 26th 2020

Value of PD-L1 Testing in Metastatic Urothelial Cancer

August 26th 2020

PD-L1 Expression in Metastatic Urothelial Cancer

August 26th 2020

Current Status of Therapy: Metastatic Urothelial Cancer

August 26th 2020

Dr. McGregor on the Evolving Treatment Landscape of RCC

August 25th 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Chang on the Impact of COVID-19 on the Surgical Management of GU Cancers

August 24th 2020

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

FDA Approval Sought for Frontline Cabozantinib/Nivolumab Combo in Advanced RCC

August 24th 2020

A supplemental new drug application has been submitted to the FDA for the combination of cabozantinib and nivolumab as a treatment for patients with advanced renal cell carcinoma.

RCC Care Continues to Evolve as the COVID-19 Crisis Rages On

August 21st 2020

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.

Dr. Ravi on the Evolving Treatment Landscape of Advanced Bladder Cancer

August 20th 2020

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Dr. Jonasch on the Role of Inhibiting HIF-2α in Von Hippel-Lindau Disease–Associated RCC

August 20th 2020

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Gaining Ground With Immunotherapy in Genitourinary Malignancies

August 20th 2020

Bradley McGregor, MD, discusses some of the recent approaches that have emerged in bladder cancer and renal cell carcinoma, as well as anticipated developments in each field.

FDA Grants Durvalumab Priority Review for Fixed-Dose Use in NSCLC and Bladder Cancer

August 18th 2020

The FDA has granted a priority review designation to a supplemental biologics license application for a new 4-week, fixed-dose regimen as treatment in approved indications of non–small cell lung cancer and bladder cancer.

Dr. Sonpavde on Combining VEGF/PD-1 Inhibitors in Metastatic Urothelial Carcinoma

August 14th 2020

Guru P. Sonpavde, MD, discusses the utility of combining anti-VEGF and anti–PD-1 agents in metastatic urothelial carcinoma.

Dr. McKay on the Role of Age and Gender in Advanced RCC Outcomes

August 13th 2020

Rana R. McKay, MD, discusses the role of age and gender in advanced renal cell carcinoma outcomes.